Retatrutide 30mg
$225.00
Retatrutide (GLP-3) is a triple-receptor agonist (GLP-1/GIP/glucagon) under active clinical investigation for metabolic and weight-related research applications. Supplied as lyophilized powder, 30mg per vial. For research use only.
20 in stock
Retatrutide (LY3437943) is a next-generation triple agonist peptide that simultaneously targets GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This tri-agonist design engages three complementary metabolic pathways in a single compound, representing one of the most mechanistically comprehensive molecules studied in metabolic research.
Research Applications: The glucagon receptor activity differentiates retatrutide from dual agonists, potentially amplifying energy expenditure and hepatic lipid mobilization. Research has investigated its effects on body weight reduction, glycemic control, lipid metabolism, and non-alcoholic steatohepatitis (NASH) models. Phase 2 clinical data has shown substantial weight reduction in human trials.
Key Research Areas:
- Tri-receptor incretin pharmacology (GLP-1/GIP/glucagon)
- Obesity and body weight regulation
- Hepatic lipid metabolism and NASH models
- Glycemic control and insulin sensitivity
- Energy expenditure mechanisms
For research purposes only. Not for human or veterinary use. Store lyophilized vials at -20°C. After reconstitution with BAC water, refrigerate and use within 4–6 weeks.
Every batch sold by Alpha Peptides US is independently tested by a certified third-party laboratory. The Certificate of Analysis (CoA) below confirms the identity, purity, and net content of this product.
Testing performed by Freedom Diagnostics Testing via LC-MS/MS under standard laboratory conditions. Results are specific to the tested batch and are intended for research purposes only.
View Certificate of Analysis (PDF)Research use only. Not intended for human or veterinary use, diagnostic, therapeutic, or clinical applications.
Reviews
There are no reviews yet.